Related Experiment Video
Updated: Jun 17, 2026
04:36
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
Imatinib mesylate.
1Department of Hematology and Oncology, University of Freiburg Medical Center, Hugstetterstrasse 55, 79106, Freiburg, Germany. cornelius.waller@uniklinik-freiburg.de
Summary
Imatinib mesylate is a targeted small molecule therapy effective against chronic myeloid leukemia and gastrointestinal stromal tumors. While generally well-tolerated, resistance can develop through various mechanisms.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Imatinib mesylate (Gleevec) is a novel small molecule anticancer agent.
- It functions as a signal transduction inhibitor targeting specific protein tyrosine kinases, including Bcr-Abl.
Purpose of the Study:
- To review the role of imatinib mesylate in treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).
- To discuss the mechanisms of resistance to imatinib therapy.
Main Methods:
- Review of clinical activity and adverse events associated with imatinib.
- Analysis of identified mechanisms of primary and secondary resistance to imatinib.
Main Results:
- Imatinib demonstrates remarkable clinical activity in CML and GIST, leading to its approval for these indications.
- Common adverse events include edema, muscle cramps, diarrhea, nausea, rash, and myelosuppression.
- Mechanisms of resistance involve Bcr-Abl amplification, overexpression, or mutations.
Conclusions:
- Imatinib mesylate is a well-tolerated and effective targeted therapy for CML and GIST.
- Understanding resistance mechanisms is crucial for developing next-generation tyrosine kinase inhibitors.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...